Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;127(2):175-178.
doi: 10.1111/bju.15277. Epub 2020 Nov 13.

Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation

Ivo G Schoots  1   2 , Anwar R Padhani  3
Affiliations
Review

Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation

Ivo G Schoots et al. BJU Int. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Fig. 1
Fig. 1
Risk‐adapted matrix table for guidance in biopsy decision, based on PSAD and on MRI risk assessments. The continuum of estimated risks of having a biopsy‐detectable prostate cancer are categorised into low‐ (not elevated), intermediate‐ and high‐risk (elevated). Generally, men at higher risk of having clinically significant prostate cancer require biopsy regardless of how risk is estimated. The MRI risk assessment is categorised into low (PI‐RADS 1 or 2), intermediate (PI‐RADS 3) or high (PI‐RADS 4–5) risk of having a biopsy‐detectable clinically significant prostate cancer. Each cell ascribes a different biopsy action, based on the results of Table 1. This matrix table may help guide biopsy‐decision management, while awaiting the validation of multivariable MRI prediction tools.
See this image and copyright information in PMC

References

    1. Drost FH, Osses DF, Nieboer D et al. Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019; 4: CD012663 - PMC - PubMed
    1. Padhani AR, Barentsz J, Villeirs G et al. PI‐RADS steering committee: the PI‐RADS multiparametric MRI and MRI‐directed biopsy pathway. Radiology 2019; 292: 464–74 - PMC - PubMed
    1. Schoots IG, Padhani AR. Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol 2020; 38: 531–45 - PMC - PubMed
    1. Schoots IG, Roobol MJ. Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions. World J Urol 2020; 38: 517–29 - PMC - PubMed
    1. Boesen L, Nørgaard N, Løgager V et al. Prebiopsy biparametric magnetic resonance imaging combined with prostate‐specific antigen density in detecting and ruling out Gleason 7–10 prostate cancer in biopsy‐naive men. Eur Urol Oncol 2019; 2: 311–9 - PubMed

Substances